Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia

Fig. 6

Evaluation of CX-4945 and DEC in patient-derived xenograft mice. a Xenograft mice of three different B-ALL patients (0122, 0152, 0159; patient characteristics were reported previously) were treated with vehicle (NaCl supplemented with 5% DMSO; BID d7–12), CX-4945 (50 mg/kg BW, BID, d7–12) or CX-4945 plus DEC (0.4 mg/kg BW, d7–10) and euthanized when PB blast frequency in controls reached 25%. The amount of patient-derived B-ALL tumor cells in BM, spleen and PB was assessed by CD45-FITC/CD19-PE staining and subsequent flow cytometry (mean + SD; vehicle: n = 4–5 animals per patient, treatment groups: n = 1–2 animals per patient). b AKT and PTEN activity status was analyzed in PDX mice spleen cells by western blot of phosphorylated and total protein forms. c Cytospin preparations of cells isolated from spleens of patient 0152 derived mice. Slides were stained with Pappenheim and evaluated using the EVOS xl core microscope and 100x magnification)

Back to article page